ATE303793T1 - Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes - Google Patents
Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffesInfo
- Publication number
- ATE303793T1 ATE303793T1 AT02713167T AT02713167T ATE303793T1 AT E303793 T1 ATE303793 T1 AT E303793T1 AT 02713167 T AT02713167 T AT 02713167T AT 02713167 T AT02713167 T AT 02713167T AT E303793 T1 ATE303793 T1 AT E303793T1
- Authority
- AT
- Austria
- Prior art keywords
- active ingredient
- pharmaceutical composition
- therapeutically active
- core
- prolonged
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN96DE2001 | 2001-01-30 | ||
PCT/IN2002/000062 WO2003063825A1 (en) | 2001-01-30 | 2002-03-22 | Pharmaceutical composition for extended/sustained release of therapeutically active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE303793T1 true ATE303793T1 (de) | 2005-09-15 |
Family
ID=27638221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02713167T ATE303793T1 (de) | 2001-01-30 | 2002-03-22 | Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030175349A1 (de) |
EP (1) | EP1469824B1 (de) |
JP (1) | JP2006508891A (de) |
KR (1) | KR100878882B1 (de) |
CN (1) | CN1301706C (de) |
AT (1) | ATE303793T1 (de) |
DE (1) | DE60206078T2 (de) |
ES (1) | ES2248529T3 (de) |
WO (1) | WO2003063825A1 (de) |
ZA (1) | ZA200406112B (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
KR20040063975A (ko) | 2001-11-30 | 2004-07-15 | 화이자 프로덕츠 인크. | 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물 |
WO2005041940A1 (en) * | 2003-10-30 | 2005-05-12 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
PL1916994T3 (pl) * | 2004-06-29 | 2014-05-30 | Takeda Pharma As | Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku |
KR20070043806A (ko) * | 2004-07-29 | 2007-04-25 | 사노피-아벤티스 | pH에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제 |
US20070077297A1 (en) | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
WO2007002597A2 (en) * | 2005-06-27 | 2007-01-04 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
CA2620406A1 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
EP1924246B1 (de) | 2005-09-15 | 2015-10-21 | Genzyme Corporation | Beutelformulierung für aminpolymere |
US7709014B2 (en) * | 2005-10-17 | 2010-05-04 | Yu Ruey J | Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
KR100702069B1 (ko) * | 2005-10-31 | 2007-03-30 | (주)이엘티사이언스 | 파라세타몰 경구용 수용산제 복합조성물 및 그 제조방법 |
US20110178112A1 (en) * | 2006-01-18 | 2011-07-21 | Evolva Sa | PPAR Modulators |
EP2012757A2 (de) * | 2006-04-24 | 2009-01-14 | Pfizer Products Incorporated | Asymmetrische membrane für arzneiabgabevorrichtungen |
US20070269492A1 (en) * | 2006-05-16 | 2007-11-22 | Per Steen | New product and use and manufacture thereof |
BRPI0717545A2 (pt) | 2006-09-29 | 2013-10-22 | Gezyme Corp | Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida |
US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
JP2010513271A (ja) | 2006-12-14 | 2010-04-30 | ゲンズイメ コーポレーション | アミド−アミンポリマー組成物 |
US20090004281A1 (en) * | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
DK2868315T3 (en) | 2007-12-04 | 2017-09-04 | Biogen Chesapeake Llc | IMPROVED FORMULATIONS AND PROCEDURES FOR FREEZING DRYING AND THEREOF, LYOFILATES PREPARED |
WO2009097443A2 (en) | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
CN101259113B (zh) * | 2008-04-21 | 2013-02-13 | 沈阳药科大学 | 依托度酸渗透泵型控释制剂 |
EP2228066A1 (de) * | 2009-03-03 | 2010-09-15 | LEK Pharmaceuticals d.d. | Pharmazeutische Zusammensetzungen eines auf Sulphonylharnstoff basierenden pharmazeutischen Wirkstoffs mit ausgezeichneten Auflösungseigenschaften |
CN101618027B (zh) * | 2009-07-16 | 2013-07-31 | 沈阳药科大学 | 醋氯芬酸双层渗透泵控释片及其制备方法 |
CN102670575A (zh) * | 2011-03-09 | 2012-09-19 | 中国药科大学 | 酮洛芬渗透泵型控释制剂及其制备方法 |
CN102133205B (zh) * | 2011-03-17 | 2013-12-11 | 山东新华制药股份有限公司 | 一种格列吡嗪渗透泵控释片的制备方法 |
CN103842330B (zh) * | 2011-09-02 | 2016-10-19 | 诺华股份有限公司 | 抗炎的取代的环丁烯二酮化合物的胆碱盐 |
CN103142565B (zh) * | 2012-04-18 | 2015-04-29 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种尼美舒利的缓释药物组合物及其制备方法 |
NO2659881T3 (de) * | 2012-04-30 | 2018-04-28 | ||
IN2015DN04161A (de) * | 2012-10-16 | 2015-10-16 | Ranbaxy Lab Ltd | |
CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
DE102015122319A1 (de) * | 2015-12-18 | 2017-06-22 | Special Coatings Gmbh & Co. Kg | Trommelbeschichtungsverfahren und -vorrichtung für kleine mengen an zu beschichtenden kleinteilen |
GB2546513B (en) | 2016-01-20 | 2020-09-16 | Cubic Pharmaceuticals Ltd | Process of preparing active pharmaceutical ingredient salts |
CN105581993B (zh) * | 2016-03-11 | 2018-06-29 | 常州欧法玛制药技术有限公司 | 一种阿司匹林渗透泵控释片及其制备方法 |
CN109303765A (zh) * | 2018-11-21 | 2019-02-05 | 南京泽恒医药技术开发有限公司 | 一种呋塞米口服溶液及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1468172A (en) * | 1973-03-28 | 1977-03-23 | Benzon As Alfred | Oral drug preparations |
US4160452A (en) * | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
DE2831164A1 (de) * | 1978-07-15 | 1980-01-24 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
GB8616669D0 (en) * | 1986-07-09 | 1986-08-13 | Merk Sharpe & Dohme Ltd | Pharmaceutical compositions |
US4880631A (en) * | 1987-09-24 | 1989-11-14 | Merck & Co., Inc. | Controlled porosity osmotic pump |
NZ226179A (en) * | 1987-09-24 | 1991-04-26 | Merck & Co Inc | Controlled porosity osmotic pump for sustained release of pharmaceutical agents |
JPH0791184B2 (ja) * | 1988-03-31 | 1995-10-04 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
US5612059A (en) * | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IL91398A (en) * | 1988-08-30 | 1994-05-30 | Pfizer | A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane |
SE9202250D0 (sv) * | 1992-07-29 | 1992-07-29 | Gacell Lab Ab | Controlled release morphine preparation |
TW235239B (de) * | 1992-11-20 | 1994-12-01 | Pfizer | |
JP4072597B2 (ja) * | 1994-12-27 | 2008-04-09 | ナムローゼ・フェンノートシャップ・オルガノン | 持続性製剤 |
US5736159A (en) * | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
GB9620709D0 (en) * | 1996-10-04 | 1996-11-20 | Danbiosyst Uk | Colonic delivery of weak acid drugs |
US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
CA2388159A1 (en) * | 1999-10-29 | 2001-05-10 | Merck & Co., Inc. | Osmotic controlled release drug delivery device |
SE0001151D0 (sv) * | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
-
2002
- 2002-03-20 US US10/101,237 patent/US20030175349A1/en not_active Abandoned
- 2002-03-22 ES ES02713167T patent/ES2248529T3/es not_active Expired - Lifetime
- 2002-03-22 KR KR1020047012012A patent/KR100878882B1/ko active IP Right Grant
- 2002-03-22 JP JP2003563519A patent/JP2006508891A/ja active Pending
- 2002-03-22 CN CNB028286693A patent/CN1301706C/zh not_active Expired - Lifetime
- 2002-03-22 DE DE60206078T patent/DE60206078T2/de not_active Expired - Lifetime
- 2002-03-22 EP EP02713167A patent/EP1469824B1/de not_active Expired - Lifetime
- 2002-03-22 WO PCT/IN2002/000062 patent/WO2003063825A1/en active Search and Examination
- 2002-03-22 AT AT02713167T patent/ATE303793T1/de active
-
2004
- 2004-07-30 ZA ZA200406112A patent/ZA200406112B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006508891A (ja) | 2006-03-16 |
ZA200406112B (en) | 2006-06-28 |
WO2003063825A1 (en) | 2003-08-07 |
EP1469824B1 (de) | 2005-09-07 |
ES2248529T3 (es) | 2006-03-16 |
DE60206078D1 (de) | 2005-10-13 |
CN1622799A (zh) | 2005-06-01 |
KR100878882B1 (ko) | 2009-01-15 |
KR20040091006A (ko) | 2004-10-27 |
EP1469824A1 (de) | 2004-10-27 |
CN1301706C (zh) | 2007-02-28 |
US20030175349A1 (en) | 2003-09-18 |
DE60206078T2 (de) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE303793T1 (de) | Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes | |
MD4180C1 (ro) | Procedeu de fabricare a compoziţiilor farmaceutice cu conţinut de rifaximină sub formă de microgranule gastrorezistente, compoziţii şi utilizarea lor în tratamentul afecţiunilor inflamatoare ale intestinelor | |
HRP20100682T1 (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof | |
TR200002059T2 (tr) | Devamlı salınan bileşim, üretim yöntemi ve kullanımı. | |
CY1110264T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν ευαισθητα σε ρη συμπολυμερη τυπου μπλοκ και υδροφοβο φαρμακο | |
WO2007036952A3 (en) | Novel sustained release dosage form | |
NL2000281A1 (nl) | Vaste farmaceutische samenstellingen die pregabaline bevatten. | |
DE60036534D1 (de) | Feste pharmazeutische formulierungen auf basis von sulfoalkylethern des cyclodextrins zur verzögerten freisetzung | |
DE69917866D1 (de) | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe | |
EA200702520A1 (ru) | Составы для изменения биофизических свойств слизистой оболочки | |
RS50303B (sr) | Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem | |
ATE358160T1 (de) | Ph-responsive biologisch abbaubare polymilchsäurederivate, die polymermicellen bilden, und deren verwendung zur zufuhr von schlecht wasserlöslichen arzneistoffen | |
BG108516A (en) | Pharmaceutical formulation | |
WO2009072334A1 (ja) | 製剤用核粒子 | |
WO2020222139A9 (en) | Formulations and methods for drug instillation into the bladder and treatment of bladder ailments | |
DZ3473A1 (fr) | Formulation pharmaceutique a liberation prolongee independante de la force ionique. | |
ATE464878T1 (de) | Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl | |
BRPI0416298A (pt) | método para manufatura de poliacroleìna | |
EA200300110A1 (ru) | Композиция элетриптана в виде частиц | |
HRP20090190T1 (en) | Pharmaceutical composition comprising a salt of mirtazapine | |
ATE366733T1 (de) | Pioglitazonsulfat, pharmazeutische zusammensetzungen und deren anwendung | |
JP2005526061A5 (de) | ||
NO20025461L (no) | Nye formuleringer av <alfa>-(2,4-disulfofenyl)-N-tert- butylnitron | |
DE60004204D1 (de) | Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung | |
UA83036C2 (ru) | Фармацевтическая композиция в виде гидрогеля для трансдермального введения в организм действующих веществ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1469824 Country of ref document: EP |